Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study - Takeaways - MDSpire

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study

  • By

  • Joseph Magagnoli

  • Tammy H. Cummings

  • Meenakshi Ambati

  • S. Scott Sutton

  • Jayakrishna Ambati

  • December 26, 2025

  • 0 min

Share

  • 1

    Xanthine oxidase inhibitors (XOis) are essential for managing gout and hyperuricemia, potentially affecting cardiovascular risk.

  • 2

    Discontinuation of XOis may lead to increased cardiovascular events, including acute myocardial infarction and ischemic stroke.

  • 3

    The study utilized a large national claims database to analyze the impact of XOi withdrawal on acute cardiovascular diagnoses.

  • 4

    Patients with gout who discontinued XOis showed a higher risk of acute cardiovascular events compared to those who continued therapy.

  • 5

    The research highlights the need for further investigation into the cardiovascular effects of XOi withdrawal in outpatient populations.

Original Source(s)

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study

  • by Joseph Magagnoli, Tammy H. Cummings, Meenakshi Ambati, S. Scott Sutton, Jayakrishna Ambati

  • December 26, 2025

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Neutrophil extracellular traps in gout: from immune defense to pathological dynamic equilibrium

Allopurinol, gout, and cardiovascular risk